CoChat

Treatment of Men with Central Hypogonadism: Alternatives for Testosterone Replacement Therapy

Open access
Ide, Veerle, Vanderschueren, Dirk, Antonio, Leen · 2020 · International Journal of Molecular Sciences

The DOI matches its Crossref record; 69 of the 69 references it cites were found in a registry or an index; 25 of the 158 sources its claims cite were checked for support.

Abstract

Central hypogonadism is a clinical condition, characterized by sexual symptoms and low serum testosterone levels, due to an impaired function of the hypothalamus or pituitary gland. Testosterone replacement therapy (TRT) is the standard treatment for hypogonadism, but it has some disadvantages. TRT is not a good option in men wishing to preserve fertility, nor in men with (a high risk of) prostate cancer, polycythemia, thrombophilia and severe cardiovascular disease. In this review, we discuss alternative treatments for central hypogonadism. If reversible causes are present, non-pharmacological interventions can be therapeutic. Gonadotropins are a good alternative to TRT when fertility is desired in the near future though they require frequent injections. Clomiphene citrate and tamoxifen seem to be a safe alternative for the treatment of functional central hypogonadism in men, as several studies reported a significant increase in testosterone levels with these drugs. However, their use is off-label and data supporting the efficacy of clomiphene citrate and tamoxifen on hypogonadal symptoms are insufficient. For this reason, clomiphene citrate and tamoxifen should not be used in routine clinical practice to treat sexual symptoms in men with central hypogonadism.

Overview

CoChat Summary

## TL;DR

This review summarizes alternatives to testosterone replacement therapy (TRT) for men with central hypogonadism, especially when fertility must be preserved or TRT is otherwise unsuitable. The authors conclude that gonadotropins are the best-supported alternative for fertility-directed treatment, while clomiphene citrate and tamoxifen may raise testosterone in functional central hypogonadism but should not be used routinely for sexual symptoms because symptom-benefit data are insufficient.

## Key findings

  • TRT is described as the standard treatment for hypogonadism, but it is not a good option for men wishing to preserve fertility and is contraindicated or unsuitable in men with prostate cancer risk, polycythemia, thrombophilia, severe cardiovascular disease, and some other conditions.
  • Gonadotropin therapy induced spermatogenesis in 75% of patients in one meta-analysis of men with hypogonadotropic hypogonadism and azoospermia; in another combined analysis of 100 patients, spermatogenesis was induced in 84% and 69% reached sperm concentrations ≥1.5 × 10^6/mL.
  • A retrospective study in hypogonadotropic hypogonadism found hCG alone led to testicular growth in 42/84 (50%) and spermatogenesis in 34/84 (40%), while hCG + hMG led to testicular growth in 56/74 (76%) and spermatogenesis in 48/74 (65%).
  • Clomiphene citrate and tamoxifen were reported in several studies to significantly increase testosterone, but evidence for symptom improvement is inconsistent; one study in 86 men showed improvement in 5/10 ADAM questions, while an RCT in 78 obese men found no difference in overall ADAM score after 12 weeks.
  • In one retrospective analysis of 400 men treated with clomiphene citrate for a mean of 25.5 months, side effects were reported in 8%; another study of 46 men reported no side effects over 12 months.

## Methods

  • This is a narrative review of treatments for central hypogonadism, organized into non-pharmacological interventions, gonadotropins, pulsatile GnRH, SERMs (clomiphene citrate, tamoxifen), and aromatase inhibitors.
  • The paper synthesizes evidence from studies cited in the text, including meta-analyses, randomized controlled trials, retrospective studies, and small observational studies; no new patient sample is presented.
  • The main analysis is qualitative comparison of treatment options based on effects on testosterone, fertility/spermatogenesis, hypogonadal symptoms, and adverse effects.

## Limitations

  • The paper states that studies of clomiphene citrate and tamoxifen are often heterogeneous, frequently lack clear descriptions of the study population, and often do not distinguish organic from functional central hypogonadism.
  • It explicitly notes that high-quality RCTs with clear population definitions and long-term follow-up are missing for clomiphene citrate and tamoxifen, so evidence is insufficient to justify their routine use for sexual symptoms.
  • Evident from the text: this is a review, so conclusions depend on the quality and consistency of previously published studies rather than direct original data.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.3390/ijms22010021

Cites

69 of 69 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 Overview of the different causes of central hypogonadism. CHH: congenital hypogonadotropic hypogonadism.
Figure 1 Overview of the different causes of central hypogonadism. CHH: congenital hypogonadotropic hypogonadism.CC BY · PubMed Central
Figure 2 Flowchart to guide the choice of treatment for central hypogonadism. The use of clomiphene citrate, tamoxifen and AIs is off-label in male hypogonadism. The effect of these drugs on hypogonadal symptoms has not been proven. TRT: testosterone replacement therapy, GnRH: gonadotropin releasing hormone, CC: clomiphene citrate, AIs: aromatase inhibitors.
Figure 2 Flowchart to guide the choice of treatment for central hypogonadism. The use of clomiphene citrate, tamoxifen and AIs is off-label in male hypogonadism. The effect of these drugs on hypogonadal symptoms has not been proven. TRT: testosterone replacement therapy, GnRH: gonadotropin releasing hormone, CC: clomiphene citrate, AIs: aromatase inhibitors.CC BY · PubMed Central

Verification

Claims the paper makes

23 Valid · 0 Not valid · 89 Not checked · 16 Own results and interpretations

82 more claims · 11 with their cited sources checked

Create a free account to see all 128 claims and to verify the 11 references still open.

See all claims — free account
  • It may state two separate claims as one. 33
  • Probably not a substantial claim. 9

Create a free account to see these claims.

Citations

Cites

Cited by

See all 101

Metadata

Authors
Ide, V., Vanderschueren, D., & Antonio, L.
Affiliations
Universitair Ziekenhuis Leuven (BE)
Corresponding author
Antonio, Leen
Venue
International Journal of Molecular Sciences
Publisher
MDPI AG
Published
2020-12-22
Volume
22
Issue
1
Pages
21
ISSN
1422-0067 (ISSN-L)
OpenAlex
W3114028270
Cited by
101
References
69
Citations by year
2026: 12 · 2025: 15 · 2024: 33 · 2023: 25 · 2022: 11 · 2021: 4 · 2020: 1
FWCI
1.56
Type
journal article
Language
en
Open access
Locations
  • International Journal of Molecular Sciences (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, other-oa)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Lirias (submittedVersion, other-oa)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
  • Health Sciences › Medicine › Reproductive Medicine › Hypothalamic control of reproductive hormones
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
Keywords
central hypogonadism, testosterone replacement therapy, alternative treatment, gonadotropins, clomiphene citrate, tamoxifen, male hypogonadism, fertility preservation, off-label drug use, sexual symptoms, testosterone levels
MeSH terms
Androgens, Clomiphene, Fertility, Humans, Hypogonadism, Male, Testosterone, Treatment Outcome, Hormone Replacement Therapy, Selective Estrogen Receptor Modulators

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.